Cerus (CERS) to Release Earnings on Thursday

Cerus (NASDAQ:CERS) is set to post its quarterly earnings results after the market closes on Thursday, May 2nd. Analysts expect Cerus to post earnings of ($0.04) per share for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

Cerus (NASDAQ:CERS) last posted its earnings results on Tuesday, March 5th. The biotechnology company reported ($0.01) earnings per share for the quarter, hitting the consensus estimate of ($0.01). Cerus had a negative net margin of 23.98% and a negative return on equity of 67.17%. The business had revenue of $46.77 million for the quarter, compared to analyst estimates of $46.80 million. On average, analysts expect Cerus to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Cerus Stock Down 1.2 %

CERS opened at $1.66 on Thursday. The firm’s 50-day simple moving average is $1.99 and its 200-day simple moving average is $1.85. The company has a debt-to-equity ratio of 1.12, a quick ratio of 1.55 and a current ratio of 2.14. Cerus has a twelve month low of $1.21 and a twelve month high of $3.08. The firm has a market cap of $300.92 million, a price-to-earnings ratio of -7.90 and a beta of 1.29.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $3.00 target price on shares of Cerus in a report on Wednesday, March 6th. Craig Hallum assumed coverage on shares of Cerus in a report on Friday, April 12th. They set a “buy” rating and a $5.00 price objective on the stock. Finally, Stephens reissued an “equal weight” rating and set a $2.50 price objective on shares of Cerus in a report on Thursday, March 7th.

Insiders Place Their Bets

In other news, insider Chrystal Jensen sold 17,460 shares of the firm’s stock in a transaction dated Wednesday, March 13th. The shares were sold at an average price of $2.06, for a total value of $35,967.60. Following the transaction, the insider now owns 508,736 shares of the company’s stock, valued at approximately $1,047,996.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, insider Chrystal Jensen sold 17,460 shares of the firm’s stock in a transaction dated Wednesday, March 13th. The shares were sold at an average price of $2.06, for a total value of $35,967.60. Following the transaction, the insider now owns 508,736 shares of the company’s stock, valued at approximately $1,047,996.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Richard J. Benjamin sold 29,378 shares of the firm’s stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $2.40, for a total transaction of $70,507.20. Following the completion of the transaction, the insider now directly owns 478,061 shares in the company, valued at approximately $1,147,346.40. The disclosure for this sale can be found here. Insiders have sold a total of 177,516 shares of company stock valued at $372,912 in the last 90 days. 7.05% of the stock is currently owned by insiders.

About Cerus

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.